Elizabeth Charytonowicz

Author

Memorial Sloan Kettering Cancer Center

Also Known As

E Charytonowicz, E. Charytonowicz, Elizabeth CHARYTONOWICZ, Elizabeth Charytonowicz

Publications

2.4K

Citations

H-Index

Concepts

All Affiliations

Memorial Sloan Kettering Cancer Center Columbia University Icahn School of Medicine at Mount Sinai Albert Einstein College of Medicine Edith Cowan University

About

Elizabeth Charytonowicz is an author at Memorial Sloan Kettering Cancer Center specializing in medicine, pathology, and tumor biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	14	1.9K
2	Cell Biology	8	8	1.1K
3	Health Sciences	1	1	32
4	Biostatistics	1	1	35
5	Cellular Physiology	1	1	19

Elizabeth Charytonowicz

Publications

2.1K

Citations

H-Index

Page 1

	Year	Citations
Suppression of Acquired Docetaxel Resistance in Prostate Cancer through Depletion of Notch- and Hedgehog-Dependent Tumor-Initiating Cells Josep Domingo‐Domenech, Samuel J. Vidal, Verónica Rodríguez-Bravo, Cancer Cell Lineage PlasticityUrologyOncologyAcquired Docetaxel ResistanceMedicine	2012	432
The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas Eva Hernando, Elizabeth Charytonowicz, Mária Dudás, Nature Medicine Akt-mtor PathwayMedicineCritical RolePathologyTumor Suppressor	2007	285
Loss of p63 Expression Is Associated with Tumor Progression in Bladder Cancer Marshall Urist, Charles J. Di Como, Ming‐Lan Lu, American Journal Of Pathology UrologyGenitourinary CancerMedicineTumor ProgressionPathology	2002	258
Cooperative effects of p53 and pRB alterations in primary superficial bladder tumors. Carlos Cordon‐Cardo, Zuo‐Feng Zhang, Guido Dalbagni, PubMed Surgical OncologyPathologyTumor BiologyOncologyGenitourinary Cancer	1997	220
Molecular profiling of bladder cancer using cDNA microarrays: defining histogenesis and biological phenotypes. Marta Sänchez‐Carbayo, Nicholas D. Socci, Elizabeth Charytonowicz, PubMed Dna MicroarraysPathologyGene Expression ProfilingTumor BiologyMolecular Profiling	2002	198
Gene Discovery in Bladder Cancer Progression using cDNA Microarrays Marta Sänchez‐Carbayo, Nicholas D. Socci, Juan José Lozano, American Journal Of Pathology UrologyFunctional GenomicsGenitourinary CancerGene DiscoveryMedicine	2003	180
Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome, assessed by conventional and array-based methods. Ming-Lan Lu, Friedrik P. Wikman, Torben F. Ørntoft, PubMed Tumor BiologyUrological ResearchUrologyArray-based MethodsTumor Heterogeneity	2002	143
p53 nuclear overexpression: an independent predictor of survival in lymph node--positive colorectal cancer patients. Z S Zeng, A. Sadeki Sarkis, Zuo‐Feng Zhang, Journal of Clinical Oncology	1994	130
PPARγ agonists enhance ET-743–induced adipogenic differentiation in a transgenic mouse model of myxoid round cell liposarcoma Elizabeth Charytonowicz, Melissa Terry, Katherine Coakley, Journal of Clinical Investigation PathologyTransgenic Mouse ModelCancer BiologyTumor BiologyTissue Development	2012	63
Tumor suppressor role for myopodin in bladder cancer: loss of nuclear expression of myopodin is cell-cycle dependent and predicts clinical outcome Marta Sänchez‐Carbayo, Karin Schwarz, Elizabeth Charytonowicz, Oncogene Nuclear ExpressionUrologyOncologyMedicineTumor Suppressor Role	2003	51

Page 1